H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.
1. An H5 protein of influenza virus, said H5 protein comprises amino acids 17-568 of amino acid sequence SEQ ID NO:4 and includes the amino acid 223N and the modification 328K+, wherein numbering of the amino acid positions of the H5 protein refers to the amino acid position as exemplarily given in SEQ ID NO:1 and wherein the modification 328K+ means that a second Lysine (K+) is inserted at amino acid position 328 of said H5 protein.
2. The H5 protein according to claim 1 , wherein said H5 protein has the amino acid 94N.
3. The H5 protein according to claim 1 , wherein said H5 protein has the amino acid 120N.
4. The H5 protein according to claim 1 , wherein said H5 protein has the amino acid 155N.
5. The H5 protein according to claim 1 , wherein said H5 protein is originated from an avian influenza virus.
6. A vaccine comprising
a. a H5 polypeptide comprising amino acids 17-568 of amino acid sequence SEQ ID NO:4 and including the amino acid 223N and the modification 328K+, wherein numbering of the amino acid positions of the H5 polypeptide refers to the amino acid position as exemplarily given in SEQ ID NO:1 and wherein the modification 328K+means that a second Lysine (K+) is inserted at amino acid position 328 of said H5 polypeptide, the nucleic acid molecule encoding said H5 polypeptide, or the vector comprising said nucleic acid molecule encoding said H5 polypeptide, and
b. a pharmaceutical acceptable carrier and/or excipient.
7. The vaccine according to claim 6 , wherein said excipient is one or more adjuvants.
8. The vaccine according to claim 7 , wherein said adjuvant is an EMULSIGEN®-based adjuvant.
9. The vaccine according to claim 6 , wherein said vaccine comprises one or more further antigens.
10. The vaccine according to claim 9 , wherein said further antigen is an antigen of a poultry or mammalian pathogen.
11. The vaccine according to claim 10 , wherein said further antigen is H3, H7, or H9 of influenza virus.
12. A method for producing the H5 protein of claim 1 , wherein said method comprises the steps of:
a. isolating or amplifying the nucleic acid that codes for said H5 protein;
b. cloning said H5 encoding nucleic acid in an expression vector; and
c. expressing said H5 protein.
13. The method according to claim 12 , wherein the expression vector is a recombinant baculovirus.
14. The method according to claim 12 wherein said H5 protein is expressed in insect cells.
15. A kit of parts comprising:
a. an H5 polypeptide comprising amino acids 17-568 of amino acid sequence SEQ ID NO:4 and including the amino acid 223N and the modification 328K+, wherein numbering of the amino acid positions of the H5 polypeptide refers to the amino acid position as exemplarily given in SEQ ID NO:1 and wherein the modification 328K+means that a second Lysine (K+ is inserted at amino acid position 328 of said H5 polypeptide; and
b. a package leaflet indicating the use of such H5 protein, nucleic acid molecule, vector or vaccine of a) for the treatment or prophylaxis of infections caused by influenza virus.
16. The kit according to claim 15 , wherein said kit comprises at least one further antigen of poultry or mammalian pathogen.